HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Left Out Of $80M For Stopping Consumer Product Fraud In Latest US COVID-19 Relief Act

Executive Summary

American Rescue Plan Act appropriated $50m to Consumer Product Safety Commission and $30.4m to Federal Trade Commission for COVID-19-related enforcement. Neither agency received funding for pandemic-related enforcement in previous relief packages.

You may also be interested in...



Consumers Vulnerable To False Supplement Claims, Plus Products For ‘Gym Rats’ Get US DoJ Attention

DoJ criminal prosecutions in supplement sector have focused on undisclosed steroids targeted for consumers typically aware the products contain more than labels indicate. But weighing consumers’ vulnerability to false claims also factors in federal prosecutors’ decisions on seeking criminal charges in consumer health products sector.

US COVID-19 Relief Package Boosts Pharma Manufacturing Programs – More To Come?

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

Congress Gives FDA Authority To Destroy Counterfeit Devices Found In Imports

Safeguarding Therapeutics Act, approved by the House in September and by the Senate on 8 December, targets the proliferation of shipments into the US containing fake testing kits, cures and vaccines that claim to address coronavirus, some available OTC.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel